About Us

We're here to transform the lives of people affected by neuromuscular disease.

Press Releases

PTC Therapeutics Announces FDA Acknowledgment of New Drug Application Filing for Translarna™ for the Treatment of Nonsense Mutation Duchenne Muscular Dystrophy

Submitted by KReddy on Wed, 03/08/2017 - 09:39
FDA Accepts sBLA Filing of Soliris® (Eculizumab) as a Potential Treatment for Patients with Refractory Generalized Myasthenia Gravis (gMG)

Submitted by KReddy on Wed, 03/08/2017 - 09:43
Eleven Major Patient Groups Outline Joint Position on Health Care Reform

Submitted by KReddy on Mon, 03/06/2017 - 14:46

Washington, D.C., March 6, 2017 – A coalition of eleven nonpartisan patient groups today laid out a joint set of goals they want Congress to focus on as it considers changes to the Affordable Care Act.
Nationwide Thousands of Businesses Unite to Help Save Lives through MDA Shamrocks

Submitted by KReddy on Wed, 03/01/2017 - 09:27

The program now in its 35^th year has raised millions to support families with muscular dystrophy, ALS and related life-threatening diseases.
MDA Names Kristine Welker Interim CEO

Submitted by KReddy on Mon, 02/13/2017 - 15:37

CHICAGO, February 13, 2017— MDA today announced that Kristine Welker, a member of the Board of Directors, has been appointed Interim President and Chief Executive Officer, effective immediately, and is succeeding Steve Derks, MDA's President and Chief Executive Officer since December 2012, who is stepping down after helping lead MDA through this important time of transformation.
MDA Celebrates News of FDA Approval of Emflaza for Treatment of Duchenne Muscular Dystrophy

Submitted by KReddy on Thu, 02/09/2017 - 12:21

CHICAGO, February 9, 2017— The Muscular Dystrophy Association today welcomed news of the U.S. Food and Drug Administration’s decision to grant approval for deflazacort (brand name Emflaza), under development by Marathon Pharmaceuticals, to treat the most common childhood form of muscular dystrophy.

« first
‹ previous
…
6
7
8
9
10
11
12
13
14
…
next ›
last »

Our Story

Our Team

Resources

Care Centers

Family Seminars

Resource Center

Summer Camp

Our Approach

For Researchers

For Clinicians

Participate

Donate

Partner

About Us

Press Releases

PTC Therapeutics Announces FDA Acknowledgment of New Drug Application Filing for Translarna™ for the Treatment of Nonsense Mutation Duchenne Muscular Dystrophy

FDA Accepts sBLA Filing of Soliris® (Eculizumab) as a Potential Treatment for Patients with Refractory Generalized Myasthenia Gravis (gMG)

Eleven Major Patient Groups Outline Joint Position on Health Care Reform

Nationwide Thousands of Businesses Unite to Help Save Lives through MDA Shamrocks

MDA Names Kristine Welker Interim CEO

MDA Celebrates News of FDA Approval of Emflaza for Treatment of Duchenne Muscular Dystrophy

Find MDA
in your Community

Sign Up for MDA News & Updates

About Us

Press Releases

PTC Therapeutics Announces FDA Acknowledgment of New Drug Application Filing for Translarna™ for the Treatment of Nonsense Mutation Duchenne Muscular Dystrophy

FDA Accepts sBLA Filing of Soliris® (Eculizumab) as a Potential Treatment for Patients with Refractory Generalized Myasthenia Gravis (gMG)

Eleven Major Patient Groups Outline Joint Position on Health Care Reform

Nationwide Thousands of Businesses Unite to Help Save Lives through MDA Shamrocks

MDA Names Kristine Welker Interim CEO

MDA Celebrates News of FDA Approval of Emflaza for Treatment of Duchenne Muscular Dystrophy

Find MDA in your Community

Find MDA
in your Community